Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group

Recent Results Cancer Res. 1988:110:36-43. doi: 10.1007/978-3-642-83293-2_5.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Mitomycins / adverse effects
  • Prognosis
  • Random Allocation
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / surgery

Substances

  • Mitomycins
  • Mitomycin
  • Doxorubicin
  • Fluorouracil

Supplementary concepts

  • FAM protocol